PROK: ProKidney Inc. Earnings growth forecast for next year

How can millions of patients be freed from dialysis? ProKidney Corp. (PROK) is addressing this through kidney regeneration using the body's own cells. The change in the consensus earnings per share forecast, based on data from the GURU.Markets chart, demonstrates a trend where the indicator reached the level of 0.90. The success of the REACT technology will provide the company with pricing power, although development is currently constrained by colossal R&D expenditures.

PROK - ProKidney Inc. Expected net earnings per share growth next year over the range 04/28/2023 - 11/14/2026

prokidney.com - analytical breakdowns and key metrics (PROK)

- price and consensus price forecast:

Price Chart ProKidney Inc.|PROK - Broker Consensus Forecast

- market capitalization information:

Market Capitalization ProKidney|PROK - Total Enterprise Value

- book capitalization indicators:

Accounting Value per Share ProKidney|PROK - Total Stockholders' Equity|Market Value to Book Value Ratio prokidney.com|PROK - Total Asset Value of Company

- issuer credit burden and liquidity indicators:

- earnings and market ratios statistics:

PROK - Company Profit|Expected Profit ProKidney Corp.|PROK - Price to Earnings Multiple|Forward P/E Multiple ProKidney Corp.|PROK - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio ProKidney|PROK - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months ProKidney|PROK - Earnings per share for the trailing year|Quarterly EPS earnings growth prokidney.com|PROK - Net earnings per share growth this year|Net earnings per share growth forecast for next year ProKidney Corp.

- total revenue and sales volume data:

PROK - Company Total Revenue|Company Projected Revenue ProKidney Inc.|PROK - Market Capitalization-to-Revenue Ratio|Price-to-Projected Revenue Ratio ProKidney

Fundamental company analysis:PROK, ProKidney Inc.

Investments in the human capital of ProKidney Corp. (PROK) within the cell therapy sector are directly reflected in analysts' expectations for N+1 profit dynamics. This indicator calculates the percentage change in projected earnings per share, allowing for a comparison between the market consensus and fundamental business growth rates, where an increase in the metric signals profitability potential but warns of the risk of overpaying for the asset.

Main competitors